Cholesterol-induced thrombogenicity of the vessel wall: Inhibitory effect of fluvastatin

Thrombosis and Haemostasis

Volumn 87, Issue 4, 2002, Pages 748-755

  Camera, Marina ^a   Toschi, Vincenzo ^a   Comparato, Carmen ^a   Baetta, Roberta ^a   Rossi, Francesca ^a   Fuortes, Michele ^a   Ezekowitz, Michael D ^a   Paoletti, Rodolfo ^a   Tremoli, Elena ^a  

^a Dept of Pharmacological Sciences ^*  (Italy)

Author keywords

Atherosclerosis; Hypercholesterolemia; Thrombosis; Tissue factor

Indexed keywords

CHOLESTEROL; FLUINDOSTATIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN CDC42; PROTHROMBIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ARCH; ARTERY THROMBOSIS; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; DRUG EFFECT; DRUG INHIBITION; ENZYME ASSAY; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; LIPID STORAGE; MALE; NONHUMAN; PHENOTYPE; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RABBIT; RISK FACTOR; THROMBOCYTE; THROMBOGENICITY; TRANSCRIPTION REGULATION;

EID: 0036218237     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613075     Document Type: Article

References (27)

1. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
2. Tissue factor and hemostasis
3. Identification of active tissue factor in human coronary atheroma
4. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques
5. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X
6. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma
7. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. PLAC I investigation
8. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
10. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
11. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets
12. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
13. Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of HMG-CoA reductase
14. Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells
15. Vastatin inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis
16. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro
17. Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model
18. Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells
19. SREBP-2, a membrane-bound transcription factor released by sterol-regulated proteolysis
20. Role of tissue factor in adhesion of mononuclear phagocytes to and trafficking through endothelium in vitro
21. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions
22. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets
23. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion
24. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
25. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque
26. Posttranslational modification of proteins by isoprenoids in mammalian cells
27. Interaction between c-Re1 and the mitogen-activated protein kinase kinase kinase 1 signaling cascade in mediating kappaB enhancer activation